Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

Ellen M. Gravallese, MD, Now an APLAR Master

  |  

As the Asia-Pacific League of Associations for Rheumatology (APLAR) convened its 26th annual congress in Singapore this August, Ellen M. Gravallese, MD, was honored as an APLAR Master. Dr. Gravallese is currently the Theodore Bevier Bayles Professor of Medicine at Harvard Medical School, Boston, chief of the Division of Rheumatology, Inflammation and Immunity at Brigham…

Ethics Forum: The ACR Code in Practice

Prajakta Masurkar, PhD, MPharm, & Charis Meng, MD  |  

Ethical conduct is the cornerstone of any professional organization, particularly when its decisions have an impact on public health. The ACR recognizes the importance of upholding ethical standards and has established a Code of Ethics to guide its members. Here we explore the practical application of the ACR’s Code of Ethics.1 Manage Potential Conflicts Central…

Case Report: Leprosy Masquerading as Relapsing Polychondritis

Rohan Goel, MBBS, MD, Rashmi Roongta, MBBS, MD, DM, Dipendranath Ghosh, MBBS, MD, DM, & Parasar Ghosh, MD, DM  |  

Autoimmune rheumatic diseases (AIRDs) are known for their systemic presentations and multi-organ involvement. Numerous infectious diseases, particularly mycobacterial, fungal and indolent bacterial infections endemic to specific geographic regions, present with varied signs and symptoms of multi-system involvement and can mimic AIRDs. Thus, differentiating infection from an AIRD is critical to resolve competing treatment approaches. This…

Case Report: Hip Pain in End-Stage Renal Disease

Ilana P. Goldberg, MD, & Samuel Faught, MD  |  

Renal osteodystrophy is associated with chronic kidney disease (CKD) and its associated metabolic derangements, most commonly CKD stages 3–5. It is often subclassified into four histological subtypes, with definite distinctions unable to be made clinically. These four subtypes, which may only be differentiated by bone biopsy, include: osteitis fibrosa cystica, mixed uremic osteodystrophy, osteomalacia and…

Editor’s Pick: Palliative Care for Inclusion Body Myositis, a Case Report

Kamini E. Kuchinad, MD, MPH, Ambereen Mehta, MD, MPH, David Wu, MD, & Jemima Albayda, MD  |  

Inclusion body myositis (IBM) is a slowly progressing muscle disease of unknown cause that currently has no effective treatment. IBM is the most common inflammatory myopathy in older individuals, with a rising prevalence of 18.2 per 100,000 in adults older than 50.1,2 The disease characteristically affects the quadriceps and finger flexors, and in later stages…

FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA

  |  

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

What’s New in Large Vessel Vasculitis

Philip Seo, MD, MHS  |  

The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…

Summer 2024’s Awards, Appointments & Announcements in the World of Rheumatology

  |  

Dr. Megan Cooper Appointed Director of Pediatric Rheumatology & Immunology Division at WashU Megan A. Cooper, MD, PhD, a physician-scientist recognized internationally for her work in pediatric immunodeficiencies and immune dysregulation, took the reins of the Division of Pediatric Rheumatology and Immunology at Washington University School of Medicine, St. Louis, as director this past fall….